Non-Small Cell Lung Cancer CRISPR Knockout Cell Models for Drug Discovery

Lung cancer is the leading cause of cancer death worldwide, with an estimated 2.2 million new cases and 1.8 million deaths in 2020 (WHO GLOBOCAN). Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. The overall 5-year survival rate for NSCLC is about 25% (NCI SEER), but drops to less than 7% for metastatic disease. Key risk factors include tobacco smoking, radon exposure, and air pollution. Despite advances in targeted therapies and immunotherapies, acquired resistance remains a major clinical challenge.

NSCLC is an ideal model for mechanistic studies due to its well-characterized molecular subtypes (adenocarcinoma, squamous cell carcinoma, large cell carcinoma) and extensive public genomic datasets (TCGA, COSMIC). Open questions include mechanisms of resistance to EGFR and KRAS inhibitors, tumor heterogeneity, and immune evasion. Gene-edited cell models enable precise dissection of these pathways.

NSCLC development involves several key pathways:

1. EGFR signaling: Ligand binding leads to receptor dimerization and activation of downstream pathways (MAPK, PI3K/AKT). Mutations (exon 19 deletions, L858R) cause constitutive activation.

2. KRAS signaling: GTPase cycling between active GTP-bound and inactive GDP-bound states. Mutations (G12C, G12D, G12V) impair GTP hydrolysis, leading to sustained MAPK signaling.

3. TP53 pathway: Loss of p53 function disables cell cycle arrest and apoptosis, promoting genomic instability.

4. STK11/LKB1 pathway: Inactivation leads to metabolic reprogramming and increased metastatic potential.

Data from TCGA (Cancer Genome Atlas Research Network, Nature 2014) and COSMIC (Sanger Institute).

Key signaling networks in NSCLC:

• • MAPK/ERK pathway: KRAS -> RAF -> MEK -> ERK. Promotes proliferation and survival.
• • PI3K/AKT/mTOR pathway: Activated by EGFR, KRAS, or PIK3CA mutations. Drives cell growth and metabolism.
• • Wnt/beta-catenin pathway: Often hyperactivated in squamous cell carcinoma.
• • Cell cycle regulation: CDKN2A loss and CCND1 amplification are common.
• • DNA damage repair: BRCA1/2 and ATM alterations contribute to genomic instability.

Organoid cultures derived from patient tumors retain heterogeneity and are increasingly used for drug testing.

Common in vivo models:

• • Patient-derived xenografts (PDX): Implantation of human tumor fragments into immunodeficient mice. Preserves tumor architecture and mutational profile.
• • Genetically engineered mouse models (GEMM): Conditional KRAS G12D or EGFR L858R expression with Cre-Lox systems.
• • Induced models: Carcinogen exposure (e.g., urethane) in mice.

CRISPR/Cas9 technology enables the creation of isogenic cell lines that differ only in a specific genetic alteration. Examples include:

• • TP53 knockout in A549 cells to study loss of tumor suppression.
• • KRAS G12C knock-in in H1299 cells to model the most common KRAS mutation.
• • EGFR T790M knock-in in PC9 cells to study acquired resistance to first-generation EGFR inhibitors.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing clean genetic backgrounds for functional studies, drug screening, and target validation.

Knockout and knock-in lines are used to validate the role of specific genes in tumorigenesis. For example, isogenic TP53 knockout lines show enhanced proliferation and resistance to apoptosis. KRAS G12C knock-in models demonstrate constitutive MAPK activation and sensitivity to KRAS G12C inhibitors.

Isogenic pairs (e.g., EGFR wild-type vs. EGFR T790M) are used in high-throughput screens to identify compounds that overcome resistance. Gene-edited models also allow testing of combination therapies.

CRISPR-based synthetic lethality screens in isogenic backgrounds identify genes that become essential upon loss of a tumor suppressor. For example, STK11 knockout cells are vulnerable to metabolic inhibitors.